Literature DB >> 17294608

Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms.

B A Parmenter1, D R Denney, S G Lynch, L S Middleton, L M Harlan.   

Abstract

BACKGROUND: Studies examining the epsilon4 allele of the APOE gene as a factor affecting the severity of multiple sclerosis (MS) have yielded conflicting results. The focus of these studies on physical disability to the neglect of cognitive impairment is surprising in light of the associations between the epsilon4 allele and other dementia conditions. Only two studies examine the relationship between the epsilon4 allele and cognitive impairment.
METHODS: A neuropsychological test battery was administered to 263 MS patients, and their current disability status was evaluated. Genotypes were determined for APOE epsilon and for two promoter region polymorphisms (-219 G/T and -491 A/T).
RESULTS: Although effects were generally weak, female patients with the -491 AA genotype had a later age of disease onset, lower disability scores, and somewhat higher scores on the cognitive battery. Male patients with the epsilon2 allele had lower disability and higher scores on the cognitive battery. The epsilon4 allele was not related to physical disability, and there was no difference between epsilon4+ and epsilon4--patients in overall cognitive performance. However, when patients with severe cognitive impairment were identified, a greater proportion (52%) of these patients had the epsilon4 allele than those in the unimpaired group (27%).
CONCLUSION: An association with the epsilon4 allele was evident in this study, but only in cases of severe cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294608     DOI: 10.1177/1352458506070682

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  APOE epsilon4 and the cognitive genetics of multiple sclerosis.

Authors:  O Ghaffar; M Reis; N Pennell; P O'Connor; A Feinstein
Journal:  Neurology       Date:  2010-05-18       Impact factor: 9.910

Review 2.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

Review 3.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

4.  Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis.

Authors:  Ali Sazci; Gurler Akpinar; Cem Aygun; Emel Ergul; Omer Senturk; Sadettin Hulagu
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

5.  ApoE alleles, depression and positive affect in multiple sclerosis.

Authors:  L J Julian; L Vella; D Frankel; S L Minden; J R Oksenberg; D C Mohr
Journal:  Mult Scler       Date:  2009-03       Impact factor: 6.312

6.  Polymorphism of Apo lipoprotein E gene and the risk of multiple sclerosis.

Authors:  Hamid Mirmohammad Sadeghi; Ali Mohammad Sabzghabaee; Zeinab Mousavian; Mohammad Saadatnia; Shahin Shirani; Fatemeh Moazen
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

7.  The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Katline Metzger-Peter; Laurent Daniel Kremer; Gilles Edan; Paulo Loureiro De Sousa; Julien Lamy; Dominique Bagnard; Ayikoe-Guy Mensah-Nyagan; Thibault Tricard; Guillaume Mathey; Marc Debouverie; Eric Berger; Anne Kerbrat; Nicolas Meyer; Jérôme De Seze; Nicolas Collongues
Journal:  Trials       Date:  2020-06-29       Impact factor: 2.279

8.  ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.

Authors:  Farshid Mashayekhi; Saeed Sadigh-Eteghad; Amirreza Naseri; Milad Asadi; Negin Abbasi Garravnd; Mahnaz Talebi
Journal:  Neurol Sci       Date:  2021-06-12       Impact factor: 3.307

9.  Polymerase chain reaction amplification of a GC rich region by adding 1,2 propanediol.

Authors:  Zeinab Mousavian; Hamid Mir Mohammad Sadeghi; Ali Mohammad Sabzghabaee; Fatemeh Moazen
Journal:  Adv Biomed Res       Date:  2014-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.